Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...

At CTO West Coast, an expert discussed the implications of the FDA’s expedited approval programmes with a spotlight on ...

Serina also announced the departure of Remy Gross from its Board of Directors. Mr. Ledger stated, "Remy has been a trusted advisor to the team at Serina for many years. We thank Remy for his ...

Zai Lab Limited gains momentum with FDA Fast Track nod and solid earnings, signaling growth potential. Click here to find out ...

From a higher bar for regulatory clearance to pricing limitations, drug development is more expensive than ever. This has led ...

Most of the 15 million children with a rare disease have no FDA-approved treatments available to them. And when it comes to ...

In addition, Augustine today announced the founding of a Copenhagen, Denmark based subsidiary, Augustine Therapeutics Denmark ApS, which will serve as the company's hub for research related to ...

In May 2025, Denali Therapeutics Inc. announced a Phase 2/3 study of the efficacy and safety of tividenofusp alfa (DNL310), ...

Takeda is organized around five core businesses: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for over 80% of revenue. It also has a developing ...

Mirum Pharmaceuticals, Inc. today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., ...

Shifting from a regulatory role to driving innovation directly, Eydelman discusses how the Collaborative Community on ...

While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial ...